Related Experiment Video

Updated: Jun 2, 2026

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials
08:36

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials

Published on: April 19, 2024

Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a

Bo Feng1, Garabed Eknoyan, Zhong-Sheng Guo

  • 1Hepatology Institute, Peking University People's Hospital, Beijing, China.

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
|May 12, 2011
PubMed

Insights

Interferon-alfa (IFN-α) antiviral therapy significantly reduces proteinuria and stabilizes serum creatinine in patients with Hepatitis C virus (HCV)-associated glomerulonephritis. Achieving viral clearance further enhances these beneficial effects on kidney function.

Area of Science:

  • Nephrology
  • Hepatology
  • Virology

Background:

  • Hepatitis C virus (HCV) is linked to various glomerulopathies, causing kidney function decline.
  • The impact of antiviral treatments on HCV-associated kidney disease progression remains debated.
  • This study systematically analyzes interferon (IFN)-α-based therapy's effect on HCV-associated chronic kidney disease.

Purpose of the Study:

  • To evaluate the efficacy of interferon (IFN)-α-based antiviral therapy in patients with HCV-associated glomerulonephritis.
  • To assess the impact of this therapy on proteinuria and serum creatinine levels.
  • To determine if sustained virological response influences kidney function improvement.

Main Methods:

  • A meta-analysis of controlled and uncontrolled clinical trials was conducted.
  • Studies focused on IFN-α-based antiviral therapy for HCV-associated glomerulonephritis.
  • Key endpoints included improvements in proteinuria and serum creatinine levels.

Main Results:

  • Eleven trials with 225 patients showed a significant decrease in proteinuria (2.71 g/24 h) and serum creatinine (0.23 mg/dL) post-therapy.
  • Patients achieving sustained virological response (SVR) exhibited a greater reduction in proteinuria compared to non-SVR groups.
  • No significant difference in serum creatinine decrease was observed between SVR and non-SVR groups.

Conclusions:

  • Interferon-alfa (IFN-α)-based antiviral therapy is effective in reducing proteinuria and stabilizing serum creatinine in HCV-associated glomerulonephritis.
  • The therapy should be considered for patients with this condition.
  • Greater proteinuria improvement in patients with HCV RNA clearance supports a causal role of HCV in glomerulonephritis.
Abstract

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons09:11

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...